Combination therapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and FOLFOX chemotherapy) as the first treatment for advanced gastric (stomach) cancer. The goal is to see if this combination is safe and effective in shrinking tumors or slowing the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and able to be up and about (light activity is okay).
- You have been diagnosed with advanced gastric (stomach) or gastroesophageal junction cancer that cannot be completely removed by surgery, and you have not yet received treatment for the advanced stage.
- You have at least one tumor that can be measured on a scan, and you are able to take pills by mouth.
- You have no active bleeding or severe blood-related conditions, and your liver and kidney function are within acceptable limits.
- You have not had certain prior treatments (like this study's drugs) in the past year, and you do not have HER2-positive cancer or a specific genetic marker called MSI-H/dMMR.
- You do not have uncontrolled high blood pressure, significant heart or lung disease, active autoimmune conditions, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
This trial tests a combination of two drugs (one targeted therapy and one immunotherapy) given with chemotherapy before and after surgery for stomach cancer that hasn't spread far. The goal is to see if this approach can improve outcomes for people with locally advanced disease.
This study tests a combination of two medications (Sac-TMT and fruquintinib) as a second-line treatment for advanced stomach cancer. The goal is to see if this combination can help shrink tumors or slow the cancer's growth after a first treatment has stopped working.
This trial tests a combination of two drugs, fruquintinib and a PD-1 inhibitor, as maintenance treatment after initial chemotherapy for advanced stomach or gastroesophageal junction cancer. It aims to see if this maintenance approach helps keep the cancer from growing. It is for patients with stable disease or better after first-line therapy.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three drugs — a chemotherapy called irinotecan liposome, a targeted therapy called fruquintinib, and an immunotherapy called sintilimab — for people with advanced stomach cancer whose disease has worsened after their first treatment. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Gastric (Stomach) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.